公告中提到，历史交易金额截至2022年、2023年及2024年9月30日分别为2798万元、1798万元及660万元，利用率分别为99.93%、99.89%及60.00%。建议的年度上限为4000万元、6000万元及8000万元，预计未来三年的交易将根据市场需求逐年增加。Xintai Healthcare (02291) rose more than 30% in early trading. As of press release, it rose 30.92% to HK$22.1, with a turnover of HK$19.5613 million.
The Zhitong Finance App learned that Xintai Healthcare (02291) rose by more than 30% in early trading. As of press release, it had risen 30.92% to HK$22.1, with a turnover of HK$19.5613 million.
According to the news, Xintai Medical announced that it signed a framework agreement on commissioned products with Lepu Medical on October 21, 2024, with the aim of renewing the existing agreement which is about to expire. According to the new agreement, Xintai Medical will purchase a transcatheter implantable aortic valve system produced by Lepu Medical from January 1, 2025 to December 31, 2027, and obtain its exclusive authorization to sell and distribute it.
As mentioned in the announcement, the historical transaction amounts as of September 30, 2022, 2023 and 2024 were 27.98 million yuan, 17.98 million yuan and 6.6 million yuan, respectively, with utilization rates of 99.93%, 99.89% and 60.00%, respectively. The recommended annual limits are 40 million yuan, 60 million yuan, and 80 million yuan. It is expected that transactions over the next three years will increase year by year according to market demand.